Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric MATCH Subprotocol APEC1621A: Larotrectinib in NTRK Fusion-Positive Tumors
NCT03213704Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2017
- Primary completion
- Sep 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of larotrectinib in solid tumor, non-Hodgkin lymphoma (NHL), histiocytic disorder, sponsored by National Cancer Institute. Started Aug 2017; status: active, not recruiting.
02
Drugs
larotrectinib
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)histiocytic disorder
Beyond the preview
Go deeper on NCT03213704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03213704.